Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Koichi, Patel, Keyur, Bueso-Ramos, Carlos, Zhang, Jianhua, Gumbs, Curtis, Jabbour, Elias, Kadia, Tapan, Andreff, Michael, Konopleva, Marina, DiNardo, Courtney, Daver, Naval, Cortes, Jorge, Estrov, Zeev, Futreal, Andrew, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924706/
https://www.ncbi.nlm.nih.gov/pubmed/26871476
http://dx.doi.org/10.18632/oncotarget.7290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924706/
https://www.ncbi.nlm.nih.gov/pubmed/26871476
http://dx.doi.org/10.18632/oncotarget.7290

Ejemplares similares